RxDoctor Payments Data

Barbara Bisdee

Psychiatric/Mental Health · Pittsburgh, PANPI 1326192279

Payments from drug & device makers

$3,814in general payments, 2019–2025

Across 200 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$924
  • AbbVie$779
  • Teva Pharmaceuticals USA, Inc.$540
  • Otsuka America Pharmaceutical, Inc.$492
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$367
  • Johnson & Johnson$203
  • plus $509 from 6 others

What the payments were for

  • Food & beverage$3,58194%
  • Education$2336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,814 in reported general payments places this provider in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,471
Medicare patients
23
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate81$227,876
VraylarCariprazine Hcl84$113,216
IngrezzaValbenazine Tosylate11$77,350
VivitrolNaltrexone Microspheres24$38,724
LatudaLurasidone Hcl20$31,100
Abilify MaintenaAripiprazole11$30,738
Lurasidone Hcl116$14,280
Aripiprazole278$9,867
TrintellixVortioxetine Hydrobromide14$6,801
Sertraline Hcl375$5,082
Fluoxetine Hcl167$4,916
Venlafaxine Hcl ErVenlafaxine Hcl194$4,859
Paliperidone ErPaliperidone24$3,709
Lamotrigine279$3,616
Buspirone Hcl146$2,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$203$227,87681 claims
AbbVieVraylar$779$113,21684 claims
Neurocrine Biosciences, Inc.Ingrezza$195$77,35011 claims
Alkermes, Inc.Vivitrol$924$38,72424 claims
Sunovion Pharmaceuticals Inc.Latuda$146$31,10020 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$492$30,73811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →